Norway· NO-ID_BE1E02CA-7EEA-41FE-8A44-0BCDEDBBAACD
Nevanac
A nepafenac product containing nepafenac, registered in Norway by Novartis Pharma GmbH. The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Nepafenac is registered in 14 of 19 countries.
Countries holding a registration under ATC S01BC10 (nepafenac), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Nepafenac · ATC S01BC10
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Nepafenac
- Manufacturer
- Novartis Pharma GmbH
- Country
- Norway (NO)
- ATC code
- S01BC10
- ATC class
- Nepafenac
- Defined daily dose
- 0.15 mg, AT
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
- no_merkevare_idID_BE1E02CA-7EEA-41FE-8A44-0BCDEDBBAACD
- no_varenummer2993155
- gtin4150097793210
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for nepafenac.
Graded by severity as the source publishes them — 81 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nepafenac · interactions on record
81 records
- 81 moderate
Most severe, free to view
- DicoumarolB01AA01moderate
- WarfarinB01AA03moderate
- HeparinB01AB01moderate
- Antithrombin IIIB01AB02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nepafenac in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumNevanac 1 mg/mlNovartis Europharm
- CzechiaNEVANACNovartis Europharm Limited, Dublin
- FinlandNevanacNovartis Europharm Limited
- IrelandNevanac 1 mg/ml Eye drops, suspensionNovartis Europharm Limited
- IcelandNevanacNovartis Europharm Limited*
- NetherlandsNevanac 1 mg/ml oogdruppels, suspensieNovartis Europharm Limited
- PolandNevanacNovartis Europharm Limited
- SwedenNEVANAC 1 mg/ml Ögondroppar, suspensionNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Bulgaria · Апфекто
- Iceland · Nevanac
- Liechtenstein · Nevanac
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/002b5f03-3db9-4496-95d4-835d1a754123 GET /v1/drugs/002b5f03-3db9-4496-95d4-835d1a754123?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Øyedråper, suspensjon",
"source": "fest",
"status": "A",
"atc_name": "Nepafenak",
"merkevare_id": "ID_BE1E02CA-7EEA-41FE-8A44-0BCDEDBBAACD",
"name_form_strength": "Nevanac øyedr, susp 1 mg/ml",
"prescription_group": "C"
}See everything about nepafenac.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.